Constellation Energy heads into its May 11 Q1 print with analysts collectively bullish but actively trimming targets — a tension the results will be forced to resolve.
The Street remains firmly in the overweight camp, but the direction of travel on price targets has been one-way. Morgan Stanley cut its target from $385 to $360 on April 21, maintaining Overweight. Barclays followed suit, trimming slightly to $358. TD Cowen lowered to $381 on May 4, also keeping Buy. The pattern across the broader coverage universe is consistent: conviction on the long thesis, but less certainty on valuation headroom. The consensus mean price target of $367 implies roughly 21% upside from the current $303.63 close — meaningful, but down noticeably from where those targets clustered earlier in the year. The analyst consensus ranks in the 92nd percentile on the divergence between current price and target, a signal the Street sees the stock as materially undervalued at current levels.
The bull case centres on a structural earnings ramp. EPS estimates for 2027–2030 progress from $12.75 to $16.43, driven by nuclear production tax credit roll-offs, improving commodity prices, and favourable capacity auction outcomes. Forward EPS momentum ranks in the 67th percentile year-on-year, with 30-day and 90-day momentum scores of 60 and 69 respectively — solid but not exceptional. Bears point in the opposite direction: declining commodity prices, rising operations and maintenance costs, and slower progress on large-load commercial deals with hyperscalers who have pulled back from certain contracted arrangements. The EV/EBITDA multiple has expanded roughly 12% over the past 30 days to around 11.2x on ORTEX data, reflecting the stock's 11% monthly gain even as analyst targets were being cut — a compression of the margin of safety that makes the valuation debate sharper ahead of the print.
Short positioning tells a quiet story. SI at 3.4% of the free float is modest. It has crept up roughly 9% over the past month in share terms, but borrow costs have actually eased — running at 0.39% annualised, down 6% on the week — and availability is wide, suggesting no meaningful squeeze dynamic building in the lending market. Options positioning leans defensive in absolute terms, with the put/call ratio at 1.42 versus a 20-day average of 1.38, but the z-score of 0.45 indicates the skew is well within normal range. Broader institutional ownership is stable: Vanguard, BlackRock, and Capital Research all added modestly in their most recent filings. The most notable insider activity came in February, when CEO Joseph Dominguez sold 83,104 shares at $272 — well below the current price — alongside broad C-suite selling on the same date; that cluster looks more like scheduled plan activity than a directional read.
The earnings release is therefore less about whether the nuclear thesis is intact and more about whether near-term cash generation and large-load deal momentum can justify a stock that has re-rated 11% in a month while analyst targets have moved the other way.
See the live data behind this article on ORTEX.
Open CEG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
